Our policy in the Medical Programs Department of the National Psoriasis Foundation (NPF) is to ensure balance, independence, objectivity, and scientific rigor in all our educational programs.  Anyone presenting or participating in the planning of any NPF CME programs is expected to disclose to the Medical Programs Department any real or apparent affiliation(s) within the past 12 months that may have a direct bearing on the subject matter of the continuing medical education program.  The intent of this policy is to ensure continuing medical education programs that are free of commercial interests.


Andrew Blauvelt, M.D., M.B.A. has served as a scientific advisor and/or clinical study investigator for AbbVie, Aclaris, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Inc., Eli Lilly and Company, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Merck Sharp & Dohme, Novratis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, and Vidac, and as a paid speaker for Eli Lilly and Company, Janssen, Regeneron, and Sanofi Genzyme.


Planning Committee:  Andi Agnew has disclosed no relevant financial interests with any commercial interests.